Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|April 2, 2010
- Pharmaceutical Technology-04-02-2010
- Volume 34
- Issue 4
Reduced-Method Robustness Testing of Analytical Methods Driven by a Risk-Based Approach
The authors describe a novel approach for assessing method robustness. This article contains online-bonus material and was copublished with Pharmaceutical Technology Europe.
Advertisement
Please refer to the full online version of this article, located
Articles in this issue
over 16 years ago
Inside USP: USP Reaches 2500 Reference Standardsover 16 years ago
Tracking Solid-Dosage Equipmentover 16 years ago
Inside EDQM: The Role of the Pharmacopeia in a Globalized Worldover 16 years ago
More Questions than Answersover 16 years ago
Stay Current at INTERPHEXover 16 years ago
Unconventional Communicationover 16 years ago
The Effect of Overencapsulation on Disintegration and Dissolutionover 16 years ago
In the Spotlight April 2010over 16 years ago
Report from AsiaAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement